GENOPATH GbR
MH Guide for comprehensive
care of cancer patients

With head offices in Bonn, Germany, GENOPATH GbR is an association of 16 pathology institutes. The group formed to supply all member laboratories with top-quality and cutting-edge molecular diagnostic services that complement existing histological and cytological methods, making the comprehensive care available to every cancer patient.

With head offices in Bonn, Germany, GENOPATH GbR is an association of 16 pathology institutes. The group formed to supply all member laboratories with top-quality and cutting-edge molecular diagnostic services that complement existing histological and cytological methods, making the comprehensive care available to every cancer patient.

“GENOPATH wishes to offer all patients in our care the most modern and comprehensive methods in molecular pathology possible. With the MH Guide software, we now have automated interpretation of extensive tumor genetic data at our disposal. We look forward to working together with Molecular Health.”

Dr. Christoph Schmitt
Laboratory Director at GENOPATH

Challenge

The 16 laboratories of GENOPATH sought to harmonize the molecular pathology evaluations underpinning the care of cancer patients within their respective regions. A key issue was to ensure that the laboratories nevertheless had a broad menu of molecular tests to choose from.

Solution

The GENOPATH molecular laboratory performs a broad spectrum of tumor panels from different suppliers. Especially in the analysis of complex workups, as is often the case with multi-gene panels like the TSO500, output data are interpreted with MH Guide. Thus, the oncologist network supported by GENOPATH receives a standardized and comprehensive interpretation of molecular tumor data and information about therapy options.

Patient benefit

With up-to-date, comprehensive annotation of variants, each case evaluated by GENOPATH member laboratories results in an evidence-based decision about care for a patient. MH Guide enables harmonized data interpretation across laboratories and tests. Thus, the resulting reports are the basis for interactive discussions in the molecular tumor board to identify the best possible treatment, be it a targeted therapy or possibly participation in a clinical trial.

More case studies

OncoNet Rhein-Main e. V.

A healthcare network provides effective and targeted cancer care

View

Charité Institute of Pathology

A key player in cancer care builds on a broad spectrum of analytical approaches

View

Gen Era Diagnostics

A leading provider of molecular diagnostics products and services in Turkey offers MH Guide

View

OncoNet Rhein-Main e. V.

A healthcare network provides effective and targeted cancer care

View

Charité Institute of Pathology

A key player in cancer care builds on a broad spectrum of analytical approaches

View

Gen Era Diagnostics

A leading provider of molecular diagnostics products and services in Turkey offers MH Guide

View
GDPR Cookie Consent with Real Cookie Banner